NCT06880146Not yet recruiting
Cross-validation of a Predictive Model of Response to Anti-TNF Alpha Based on Oxylipin Response in Rheumatoid Arthritis
Source: ClinicalTrials.gov · Last updated 17 Mar 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The goal of this clinical trial is to use a blood test to predict whether a participant diagnosed with rheumatoid arthritis will respond to anti-TNF alpha treatment . The main questions it aims to answer is: Is the predictive model created using oxylipins effective? Participants starting anti-TNF alpha treatment will have a blood sample taken before starting treatment and 6 months afterwards.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 11 Mar 2025
- Start date
- 15 Mar 2025
- Primary completion date
- 1 Nov 2026
- Lead sponsor
- University Hospital, Clermont-Ferrand
- Diseases
- Rheumatoid arthritis
- NCT number
- NCT06880146
What you commit to
- Study type: Interventional
- Planned participants: 30
- From 15 Mar 2025 to the primary completion date, 1 Nov 2026
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Treatment with non-steroidal anti-inflammatory drugs in the 2 weeks prior to enrolment
Other illness
- Contraindication to biological treatment (cancer or history of cancer)
Other
- Protected persons (pregnant and/or breastfeeding women, persons under guardianship or conservatorship)
Who the study is looking for
- Male or female patient aged 18 years or older with rheumatoid arthritis according to ACR EULAR 2010 criteria
- Active disease as defined by DAS-28-CRP\>3.2
- Naive to targeted biologic or synthetic therapy
- Rheumatologist's decision to start anti-TNFα treatment
- Stable corticosteroid therapy ≤ 10 mg/day
- Patient enrolled in or benefiting from a social security scheme
- Patient who has given written informed consent to participate in the study
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CHU Clermont-Ferrand Coordinator of this site? Confirm its status | Clermont-Ferrand | France | Unknown status |
| Hôpital Cochin APHP Coordinator of this site? Confirm its status | Paris | France | Unknown status |
| CHU Saint-Etienne Coordinator of this site? Confirm its status | Saint-Etienne | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.